摘要
MiT家族易位性肾细胞癌主要包括Xp11.2/TFE3基因融合相关性肾细胞癌(TFE3 RCC)和t(6;11)/TFEB基因融合相关性肾细胞癌(TFEBRCC),临床病例少见,尚无标准的治疗方案,预后存在争议。对于局限性病灶,治疗首选外科手术切除,存在转移时可结合靶向药物、免疫检查点抑制剂等进行系统性治疗。基因检测的应用为实现个体化治疗提供依据。TFE3RCC侵袭性强、预后差,而TFEBRCC生物学行为常呈惰性,预后较好。
MiT family translocation renal cell carcinoma mainly includes Xpl1.2/TFE3 gene fusion-related renal cell carcinoma(TFE3 RCC)and t(6;11)/TFEB gene fusion-related renal cell carcinoma(TFEB RCC),which is rare and there is no standard treatment plan yet,and the prognosis is still controversial.For localized lesions,surgery is the first choice for treatment,and systemic treatment such as targeted drugs and immune checkpoint inhibitors can be combined when there is metastasis.The application of gene testing provides the basis for personalized treatment.TFE3 RCC is highly invasive and has a poor prognosis,while TFEB RCC usually has a biological behavior of inertia and a better prognosis.
作者
王军卫
夏丹
汪朔
王平
Wang Junwei;Xia Dan;Wang Shuo;Wang Ping(Department of Urology,the First People's Hospital of Wenling city,Wenling 317500,China;Department of Urology,the First Affiliated Hospital of Zhejiang University Medical College,Hangzhou 310006,China)
出处
《中华泌尿外科杂志》
CAS
CSCD
北大核心
2023年第5期394-397,共4页
Chinese Journal of Urology
基金
国家自然科学基金(81772270)。
关键词
癌
肾细胞
MiT家族易位
转录因子E3
转录因子EB
Carcinoma,renal cell
MiT family translocation
Transcription factor E3
Transcription factor EB
